These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33170819)

  • 21. Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals.
    Noe DA; Bell WR; Ness PM; Levin J
    Blood; 1986 Apr; 67(4):969-72. PubMed ID: 3082391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substitution treatment of hemophilia a and b.
    Duckert F
    Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B.
    Barnbrock A; Heller C; Königs C; Budde U; Schwabe D
    Haemophilia; 2016 Sep; 22(5):e437-9. PubMed ID: 27353656
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of hemophilia B with a new clotting-factor concentrate.
    Hoag MS; Johnson FF; Robinson JA; Aggeler PM
    N Engl J Med; 1969 Mar; 280(11):581-6. PubMed ID: 5764825
    [No Abstract]   [Full Text] [Related]  

  • 25. [An unified method of one-stage quantitative analysis of factors VIII and IX. I. (Results of the studies of the working group of the All-Union Problem-Solving Commission on "Pathology of hemostasis")].
    Barkagan ZS
    Gematol Transfuziol; 1991 Apr; 36(4):33-5. PubMed ID: 1906034
    [No Abstract]   [Full Text] [Related]  

  • 26. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
    Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
    J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factor IX deficiency in Gaucher disease. An in vitro phenomenon.
    Boklan BF; Sawitsky A
    Arch Intern Med; 1976 Apr; 136(4):489-92. PubMed ID: 1267559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight.
    Bertina RM; Van Der Linden IK
    J Lab Clin Med; 1982 Nov; 100(5):695-704. PubMed ID: 7130828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B.
    McDonald A; Hoffman M; Hedner U; Roberts HR; Monroe DM
    J Thromb Haemost; 2007 Aug; 5(8):1577-83. PubMed ID: 17663728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in hemophilia B therapy.
    Horava SD; Peppas NA
    Drug Deliv Transl Res; 2017 Jun; 7(3):359-371. PubMed ID: 28243977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor IX gene therapy for hemophilia.
    Fewell JG
    Methods Mol Biol; 2008; 423():375-82. PubMed ID: 18370215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of hemophilia B: serendipitous use of continuous infusion coagulation factor IX.
    Goldsmith JC; Gordon EM
    Thromb Res; 1993 May; 70(3):265-7. PubMed ID: 8327991
    [No Abstract]   [Full Text] [Related]  

  • 33. A new drug form of blood coagulation factor IX: red blood cell-entrapped factor IX.
    Sinauridze EI; Vuimo TA; Kulikova EV; Shmyrev II; Ataullakhanov FI
    Med Sci Monit; 2010 Oct; 16(10):PI19-26. PubMed ID: 20885362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simple assay for human factor IX: use of canine hemophilia B plasma as substrate.
    Goldsmith JC; Chung KS; Roberts HR
    Thromb Res; 1978 Mar; 12(3):497-502. PubMed ID: 653637
    [No Abstract]   [Full Text] [Related]  

  • 35. Phenotypic characterization of haemophilia B - Understanding the underlying biology of coagulation factor IX.
    Tjärnlund-Wolf A; Lassila R
    Haemophilia; 2019 Jul; 25(4):567-574. PubMed ID: 31180618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Coagulation factor IX inhibitor in hemophilia B].
    Lutze G; Mittler U; Presser HJ; Urbahn H
    Z Med Lab Diagn; 1990; 31(2):113-9. PubMed ID: 2343619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of factor IX.
    Smith K
    Blood; 1986 Oct; 68(4):979-80. PubMed ID: 3756354
    [No Abstract]   [Full Text] [Related]  

  • 39. Factor IX variants of hemophilia B. The effect of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules.
    Osterud B; Kasper CK; Prodanos C
    Thromb Res; 1979; 15(1-2):235-43. PubMed ID: 483278
    [No Abstract]   [Full Text] [Related]  

  • 40. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.